on Sandoz Group AG (isin : CH1243598427)
Sandoz Launches Affordable Ranluspec® in Europe
Sandoz Group AG has introduced Ranluspec® (ranibizumab) in Europe, following the European Commission's approval in February 2026. This launch aims to expand access for patients with retinal diseases, offering an affordable alternative to Lucentis®. The move supports Sandoz's Bio100 ambition, focusing on biosimilar expansion.
Ranluspec is developed by Lupin Limited and marketed by Sandoz in the EU, excluding Germany. It treats various conditions including age-related macular degeneration and diabetic retinopathy. Christophe Delenta, Sandoz's President Europe, highlights its importance in preserving vision and enhancing life quality for patients.
This launch signifies Sandoz's strengthened presence in ophthalmology, complementing previous European and US product introductions. The commercial partnership with Lupin emphasizes Sandoz's exclusive marketing rights across most of the EU.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Sandoz Group AG news